IRIS
TOSCANI, Denise
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.639
AS - Asia 2.245
EU - Europa 1.756
SA - Sud America 369
AF - Africa 119
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 1
Totale 7.137
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.556
SG - Singapore 869
CN - Cina 775
SE - Svezia 341
IT - Italia 316
IE - Irlanda 310
BR - Brasile 293
HK - Hong Kong 182
DE - Germania 177
FI - Finlandia 168
VN - Vietnam 136
TR - Turchia 106
NL - Olanda 80
ZA - Sudafrica 75
AT - Austria 66
FR - Francia 66
CA - Canada 55
IN - India 48
RU - Federazione Russa 47
GB - Regno Unito 45
AR - Argentina 33
BE - Belgio 25
BD - Bangladesh 23
CZ - Repubblica Ceca 23
CI - Costa d'Avorio 22
MX - Messico 19
RO - Romania 19
ES - Italia 16
JP - Giappone 16
PL - Polonia 16
UA - Ucraina 12
KR - Corea 11
EC - Ecuador 10
ID - Indonesia 9
PK - Pakistan 9
AE - Emirati Arabi Uniti 8
IQ - Iraq 8
LT - Lituania 8
VE - Venezuela 8
CO - Colombia 7
CL - Cile 6
EU - Europa 6
PY - Paraguay 6
UZ - Uzbekistan 6
IL - Israele 5
BG - Bulgaria 4
IR - Iran 4
KZ - Kazakistan 4
SN - Senegal 4
TN - Tunisia 4
AZ - Azerbaigian 3
UY - Uruguay 3
AM - Armenia 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
HU - Ungheria 2
JO - Giordania 2
KE - Kenya 2
MA - Marocco 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
QA - Qatar 2
SA - Arabia Saudita 2
SC - Seychelles 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
HN - Honduras 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MZ - Mozambico 1
NG - Nigeria 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
TC - Turks e Caicos 1
TH - Thailandia 1
TW - Taiwan 1
Totale 7.137
Salva come PNG Salva come JPEG
Città #
Singapore 397
Ashburn 365
Chandler 310
Dublin 308
Dallas 240
Santa Clara 216
Beijing 215
Hong Kong 182
Parma 132
Ann Arbor 108
Boardman 103
Izmir 90
Shanghai 88
New York 86
Dearborn 74
Johannesburg 70
Los Angeles 70
Munich 70
Nanjing 64
Vienna 61
Ho Chi Minh City 58
Princeton 56
Hefei 39
Shenyang 38
Marseille 34
Buffalo 31
São Paulo 28
Hanoi 27
Helsinki 27
Jacksonville 27
Columbus 26
Wilmington 26
Brussels 25
Düsseldorf 25
Toronto 25
Kunming 24
Moscow 24
Hebei 23
Abidjan 22
Milan 20
Nanchang 20
Turku 20
Jinan 18
San Mateo 17
Brno 16
Jiaxing 16
Tianjin 16
Tokyo 15
Bremen 14
Seattle 14
Warsaw 14
Council Bluffs 13
Montreal 13
Norwalk 13
The Dalles 13
Brooklyn 12
Atlanta 11
Bologna 11
Houston 11
London 11
Seoul 11
Chicago 10
Denver 10
Frankfurt am Main 10
Kocaeli 10
Redmond 10
Stockholm 10
Woodbridge 10
Changsha 9
Focsani 9
Jakarta 9
Rome 9
Chennai 8
Poplar 8
Zhengzhou 8
Belo Horizonte 7
Guangzhou 7
Ottawa 7
Pune 7
San Francisco 7
Ankara 6
Des Moines 6
Mexico City 6
Philadelphia 6
Phoenix 6
Rio de Janeiro 6
Salvador 6
Tashkent 6
Ahmedabad 5
Amsterdam 5
Biên Hòa 5
Boston 5
Chengdu 5
Da Nang 5
Dubai 5
Guarulhos 5
Guayaquil 5
Haiphong 5
Nuremberg 5
Orem 5
Totale 4.426
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 179
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 178
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 168
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 162
The Proteasome and Myeloma-Associated Bone Disease 161
Novel targets for the treatment of relapsing multiple myeloma 159
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 158
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 157
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 154
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 148
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 146
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 140
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 139
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 138
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 136
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 134
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 131
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 130
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 130
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 127
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 126
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 126
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 125
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 124
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 123
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 121
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 121
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 121
The osteoblastic niche in the context of multiple myeloma 119
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 117
Possible targets to treat myeloma-related osteoclastogenesis 115
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 113
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 112
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 112
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 107
Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells 106
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 104
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis 103
The impact of CD56 expression in smoldering myeloma patients on early progression 102
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 102
Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives 101
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 100
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 96
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 93
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 92
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 89
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 83
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 83
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis 83
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 82
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 82
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 81
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 79
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 78
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 78
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 75
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 75
The role of proteasome inhibitors in multiple myeloma bone disease and bone metastasis: Effects on osteoblasts and osteocytes 72
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 70
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 68
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease 67
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 66
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 62
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease 58
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 50
Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance 38
Totale 7.275
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.498
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021155 0 0 0 0 0 9 14 14 56 25 12 25
2021/2022284 6 5 9 27 9 6 41 32 13 16 23 97
2022/20231.282 144 139 92 99 101 140 41 80 372 30 31 13
2023/2024556 26 37 12 14 36 185 51 22 14 35 27 97
2024/20251.663 34 75 89 154 176 171 107 75 197 128 158 299
2025/20262.144 328 307 521 379 531 78 0 0 0 0 0 0
Totale 7.275